Neuronetics

Neuronetics' mission is to provide safe, effective neuromodulation therapies for patients with psychiatric disorders who have not benefited from first-line treatments. The company has achieved commercial success with its NeuroStar TMS system, establishing it as a leading brand with over 8.2 million treatments delivered and securing broad insurance coverage. Its strategy focuses on expanding clinical indications, driving provider adoption, and leveraging a razor-and-blades business model anchored in capital equipment sales and recurring revenue from treatment sessions.

Proprietary NeuroStar Advanced Therapy system delivering transcranial magnetic stimulation (TMS), using focused magnetic pulses to induce electrical currents in the left dorsolateral prefrontal cortex (DLPFC) to modulate neural activity for treating psychiatric disorders.

Neuronetics competes directly with TMS device companies like BrainsWay and MagVenture, and indirectly with antidepressant drugs, electroconvulsive therapy (ECT), and emerging digital therapeutics. Its competitive moat is built on first-mover commercial scale, extensive insurance coverage, and a large installed base of providers.